OMX Helsinki — S&P 500 — DAX — NASDAQ 100 — STOXX 600 — EUR/USD — EUR/SEK — BTC/USD — ETH/USD — Euribor 3M — Euribor 12M —
Euractiv

Euractiv

Society and politics 63,000 subscribers

Europe must act to restore biotech competitiveness, industry warns

06.07.2026 1,689 views
Published: 06.07.2026 Category: Society and politics Views: 1,689

Episode details

Episode description

In this interview, Olaf Weppner, Vice President for Europe Region North at AbbVie, discusses the company’s footprint in Europe and the broader challenges shaping the region’s biotech sector. He highlights Europe’s strong scientific base, skilled workforce, and research infrastructure, while pointing to a decline in global competitiveness, including reduced clinical trial activity and increasing competition from other regions. The discussion explores the evolving EU policy landscape, including the Biotech Act, the General Pharmaceutical Legislation, and the Critical Medicines Act, and their implications for innovation, investment, and patient access. Olaf Weppner emphasises the importance of a more integrated and predictable regulatory framework, as well as the role of pricing, reimbursement, and cross-sector policy coherence in strengthening Europe’s life sciences ecosystem. He also reflects on expectations for the Irish Council Presidency and its potential to drive momentum on competitiveness and access to innovation. For more EU news, visit our webpage: https://www.euractiv.com/ Follow us on Social Media X: https://x.com/Euractiv Facebook: https://www.facebook.com/EURACTIV Instagram: https://www.instagram.com/euractiv/

Open the AI assistant chat. The chat loads only when you open it.